Capital flows into early-stage biotech startups have increased in the first half of 2025, with seed and Series A rounds rising to a total of $4.7 billion. However, fewer companies contributed to this total, with four companies accounting for nearly a quarter of the aggregate amount raised. This concentration indicates focused investor interest in select emerging firms. The data reflects ongoing strong venture enthusiasm for innovative biotech despite some market uncertainties.